查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1738613

全球間質性膀胱炎藥物市場規模（按類型、銷售管道、區域範圍和預測）

Global Interstitial Cystitis Drugs Market Size By Type (Oral Therapy, Intravesical Therapy), By Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

間質性膀胱炎治療藥物的市場規模及預測

間質性膀胱炎藥物市場規模在 2024 年價值 3.5664 億美元，預計到 2032 年將達到 5.0844 億美元，2026 年至 2032 年的複合年成長率為 5.00%。

間質性膀胱炎的高發生率推動了全球間質性膀胱炎藥物市場的發展。基因療法的興起對全球市場產生了正面影響。然而，這些藥物價格昂貴，副作用較多。因此，越來越多的公司正在開發再生療法和基因治療方法等創新治療方法，因為與市場上現有的傳統仿單標示外藥物相比，這些療法副作用較少。全球間質性膀胱炎藥物市場報告提供了市場的整體評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

全球間質性膀胱炎藥物市場的定義

間質性膀胱炎 (IC)，通常稱為疼痛性膀胱症候群，是一種慢性膀胱疾病，常表現為膀胱壓迫感和疼痛，以及腰背部、骨盆和下腹部疼痛。患者可能會感到疼痛，程度從輕微到嚴重不等。當患有間質性膀胱炎時，骨盆神經向大腦發出的訊號會混淆。因此，會出現尿急，但尿量通常很少。平均而言，一個人每天排尿七次，但在嚴重的 IC 病例中，每天排尿次數可達 40 至 60 次。雖然 IC 不是感染疾病，但它經常被誤認為是膀胱炎。間質性膀胱炎是由膀胱上皮層缺陷引起的，導致尿液洩漏並使尿液中的有害物質刺激膀胱壁。

口服和膀胱內治療分別是治療間質性膀胱炎的首選和次級方案。然而，沒有一種治療方法對所有患者都有效。治療方案取決於每位患者的症狀。為了消除症狀，大多數患者會嘗試各種治療方法（或多種治療方法的組合）。目前，只有兩種藥物被核准用於治療間質性膀胱炎：Elmiron 和 RIMSO-50（二甲基亞碸）。這些藥物已被證明比對症治療更有效。然而，這些藥物的價格很高。因此，許多患者主要服用仿單標示外藥物來緩解疾病症狀。

間質性膀胱炎藥物全球市場概況

間質性膀胱炎的高發生率推動了全球間質性膀胱炎藥物市場的發展。基因療法的出現對全球市場產生了正面影響。大多數核准仿單標示外列入藥品說明書的間質性膀胱炎治療藥物均為小分子化合物，這些藥物無法治癒疾病，對患者有副作用，而且價格昂貴。間質性膀胱炎患者會出現下泌尿道疾病和膀胱疼痛等症狀。女性發病率較高。該疾病還伴隨多種併發症，例如過敏、纖維肌痛和子宮內膜異位症。

間質性膀胱炎病例的不斷增加推動了對間質性膀胱炎藥物的需求。由於現有間質性膀胱炎藥物的不足，各公司正在開發副作用較少的創新治療方法，例如再生療法和基因療法。預計此類治療方法的發展將推動需求成長。因此，間質性膀胱炎的高盛行率加上基因療法的興起，預計將在預測期內推動間質性膀胱炎藥物市場規模的成長。

間質性膀胱炎的主要挑戰在於，儘管有許多可用治療方法，但缺乏普遍接受的治療方法。藥物未獲得FDA核准是全球間質性膀胱炎藥物市場發展的主要限制因素。然而，由於現有產品的療效和依從性方面的限制，間質性膀胱炎藥物市場目前處於疲軟狀態。核准治療方案有限、缺乏相關知識、對緩解疾病療法的需求是其他因素。

目錄

第1章 引言

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第2章調查方法

  • 資料探勘
  • 二次研究
  • 初步研究
  • 專家建議
  • 品質檢查
  • 最終審核
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程

第3章執行摘要

  • 市場概覽
  • 全球間質性膀胱炎藥物市場按地區分析（CAGR）
  • 全球間質性膀胱炎藥物市場（按類型）
  • 全球間質性膀胱炎藥物市場（依分銷管道）
  • 未來市場機會
  • 全球市場區隔

第4章 市場展望

  • 市場促進因素
    • 美國間質性膀胱炎盛行率高
    • 活性化研究活動
  • 市場限制
    • 消費者缺乏意識、藥品核准有限、治療費用高昂
  • 市場機會
    • 再生醫學和基因療法等創新治療方法的出現
  • COVID-19 對全球間質性膀胱炎藥物市場的影響
  • 波特五力分析
  • 產品生命線

第5章 市場類型

  • 概述
  • 口服療法
  • 膀胱內治療

第6章 分銷通路市場

  • 概述
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第7章 區域市場

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他亞太地區
  • 其他地區
    • 中東和非洲
    • 拉丁美洲

第8章競爭格局

  • 概述
  • 競爭場景
  • 企業市場排名分析

第9章 公司簡介

  • PFIZER INC.
  • JOHNSON & JOHNSON
  • KYORIN PHARMACEUTICAL
  • UCB PHARMA
  • ASTELLAS PHARMA
  • ELI LILLY AND COMPANY
  • BAYER AG
  • LIPELLA PHARMACEUTICALS
  • SEIKAGAKU CORPORATION
  • GRUNENTHAL
Product Code: 62441

Interstitial Cystitis Drugs Market Size And Forecast

Interstitial Cystitis Drugs Market size was valued at USD 356.64 Million in 2024 and is projected to reach USD 508.44 Million by 2032, growing at a CAGR of 5.00% from 2026 to 2032.

The high prevalence of interstitial cystitis is driving the global Interstitial Cystitis Drugs Market. The advent of gene therapy is positively impacting the global market. Moreover, these drugs are expensive and cause many side effects. This is encouraging companies to establish innovative treatment options such as regenerative therapy and gene therapy as these drugs cause lesser side effects compared to the conventional off-label drugs already available in the market. The Global Interstitial Cystitis Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Interstitial Cystitis Drugs Market Definition

Interstitial cystitis (IC), commonly referred to as painful bladder syndrome, is a chronic bladder issue often associated with bladder pressure and pain, as well as occasional pain in the lower back, pelvis, or lower abdomen. The patient could experience pain ranging from mild to severe. The pelvic nerve signal to the brain gets mixed up in an individual suffering from interstitial cystitis. Consequently, an urgency to urinate, often in a small volume, is observed. On average, a person urinates seven times a day; however, in severe cases of IC, urination may occur around 40-60 times a day. IC is not an infection but is often mistaken to be a bladder infection. Interstitial cystitis is caused by a defect of the epithelium layer of the bladder, leaking epithelium allows toxic substances in urine to irritate the bladder wall.

Oral therapy and intravesical therapy are the first- and second-line choices for treating interstitial cystitis, respectively. However, no one treatment is effective for all patients. The course of treatment is determined by each patient's symptoms. To eliminate the symptoms, the majority of patients try various treatments (or treatment combinations). There are currently just two approved drugs for treating interstitial cystitis, ELMIRON, and RIMSO-50 (dimethyl sulfoxide). These drugs have been shown to be more effective than symptomatic treatments. But the price of these drugs is high. Therefore, a lot of patients take off-label drugs largely to relieve the symptoms of the disease.

Global Interstitial Cystitis Drugs Market Overview

The high prevalence of interstitial cystitis is driving the global Interstitial Cystitis Drugs Market. The advent of gene therapy is positively impacting the global market. Most of the approved and off-label drugs for interstitial cystitis are small molecules, which cannot completely cure the disease, have side effects on the patients, and are expensive. Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain. Women are highly affected by this condition. Numerous comorbidities, including allergies, fibromyalgia, and endometriosis, are linked to this condition.

The increasing number of interstitial cystitis cases is driving the demand for interstitial cystitis drugs. Owing to the disadvantages of available drugs for interstitial cystitis, companies are developing innovative treatment options such as regenerative therapy and gene therapy that have fewer side effects. The development of such therapies will drive demand. Thus, the high prevalence of interstitial cystitis coupled with the advent of gene therapy will drive the Interstitial Cystitis Drugs Market size growth during the forecast period.

The major challenge for Interstitial Cystitis is that though there are several types of treatment available, no one treatment is universally acceptable. The lack of FDA approval for drugs is a major restraining factor for the Global Interstitial Cystitis Drugs Market. However, the Interstitial Cystitis Drugs Market is currently weak owing to limitations regarding the efficacy and compliance of available products. Limited approved treatment options, a lack of knowledge, and the demand for disease-modifying treatments are additional factors.

Global Interstitial Cystitis Drugs Market Segmentation Analysis

The Global Interstitial Cystitis Drugs Market is segmented on the basis of Type, Sales Channel, and Geography.

Interstitial Cystitis Drugs Market, By Type

  • Oral Therapy
  • Intravesical Therapy

Based on Type, the market is bifurcated into Oral Therapy, and Intravesical Therapy. Oral Therapy accounted for the largest market share of 56.96% in 2020, with a market value of USD 674.05 Million, and is projected to grow at a CAGR of 4.44% during the forecast period. Intravesical Therapy was the second-largest market in 2020, valued at USD 509.25 Million in 2020.

Interstitial Cystitis Drugs Market, By Sales Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on the Sales Channel, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies accounted for the largest market share of 67.69% in 2020, with a market value of USD 800.99 Million, and is projected to grow at a CAGR of 4.52% during the forecast period. Retail Pharmacies were the second-largest market in 2020, valued at USD 309.48 Million in 2020.

Interstitial Cystitis Drugs Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Players

The "Global Interstitial Cystitis Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Johnson & Johnson, Kyorin Pharmaceutical, UCB Pharma, Astellas Pharma, Bayer, Eli Lilly, Lipella Pharmaceuticals, Seikagaku Corporation, and Grunenthal. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In January 2021, The Ministry of Health, Labour and Welfare (hereinafter "MHLW") had given Kyorin Pharmaceutical Co., Ltd. permission to market interstitial cystitis "Zymso(R) Intravesical Solution 50%" (hereinafter "Zymso") in Japan. Kyorin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of KYORIN Holdings, Inc.
  • In April 2021: Kyorin Pharmaceutical Co., Ltd. a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis "Zymso(R) Intravesical Solution 50%" (hereinafter "Zymso").
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Interstitial Cystitis Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in Global Interstitial Cystitis Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW

3 EXECUTIVE SUMMARY

  • 3.1 MARKET OVERVIEW
  • 3.2 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.3 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE (USD MILLION)
  • 3.4 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL (USD MILLION)
  • 3.5 FUTURE MARKET OPPORTUNITIES
  • 3.6 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

  • 4.1 MARKET DRIVERS
    • 4.1.1 HIGH PREVALENCE OF INTERSTITIAL CYSTITIS IN THE US
    • 4.1.2 RESEARCH ACTIVITY ON A RISE
  • 4.2 MARKET RESTRAINTS
    • 4.2.1 LACK OF AWARENESS AMONG CONSUMERS, LIMITED DRUG APPROVAL, AND HIGH-COST TREATMENT
  • 4.3 MARKET OPPORTUNITIES
    • 4.3.1 EMERGENCE OF INNOVATIVE TREATMENT OPTIONS SUCH AS REGENERATIVE THERAPY AND GENE THERAPY
  • 4.4 IMPACT OF COVID -19 ON GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
  • 4.1 PORTER'S FIVE FORCES ANALYSIS
  • 4.2 PRODUCT LIFELINE

5 MARKET, BY TYPE

  • 5.1 OVERVIEW
  • 5.2 ORAL THERAPY
  • 5.3 INTRAVESICAL THERAPY

6 MARKET, BY SALES CHANNEL

  • 6.1 OVERVIEW
  • 6.2 HOSPITAL PHARMACIES
  • 6.3 RETAIL PHARMACIES USES
  • 6.4 ONLINE PHARMACIES

7 MARKET, BY GEOGRAPHY

  • 7.1 OVERVIEW
  • 7.2 NORTH AMERICA
    • 7.2.1 THE U.S.
    • 7.2.2 CANADA
    • 7.2.3 MEXICO
  • 7.3 EUROPE
    • 7.3.1 GERMANY
    • 7.3.2 FRANCE
    • 7.3.3 U.K.
    • 7.3.4 REST OF EUROPE
  • 7.4 ASIA PACIFIC
    • 7.4.1 JAPAN
    • 7.4.2 CHINA
    • 7.4.3 INDIA
    • 7.4.4 REST OF ASIA PACIFIC
  • 7.5 ROW
    • 7.5.1 MIDDLE EAST AND AFRICA
    • 7.5.2 LATIN AMERICA

8 COMPETITIVE LANDSCAPE

  • 8.1 OVERVIEW
  • 8.2 COMPETITIVE SCENARIO
  • 8.3 COMPANY MARKET RANKING ANALYSIS

9 COMPANY PROFILES

  • 9.1 PFIZER INC.
    • 9.1.1 COMPANY OVERVIEW
    • 9.1.2 COMPANY INSIGHTS
    • 9.1.3 PRODUCT BENCHMARKING
    • 9.1.4 KEY DEVELOPMENT
    • 9.1.5 SWOT ANALYSIS
  • 9.2 JOHNSON & JOHNSON
    • 9.2.1 COMPANY OVERVIEW
    • 9.2.2 COMPANY INSIGHTS
    • 9.2.3 SEGMENT BREAKDOWN
    • 9.2.4 PRODUCT BENCHMARKING
    • 9.2.5 SWOT ANALYSIS
  • 9.3 KYORIN PHARMACEUTICAL
    • 9.3.1 COMPANY OVERVIEW
    • 9.3.2 COMPANY INSIGHTS
    • 9.3.3 SEGMENT BREAKDOWN
    • 9.3.4 PRODUCT BENCHMARKING
    • 9.3.5 KEY DEVELOPMENT
    • 9.3.6 SWOT ANALYSIS
  • 9.4 UCB PHARMA
    • 9.4.1 COMPANY OVERVIEW
    • 9.4.2 COMPANY INSIGHTS
    • 9.4.3 SEGMENT BREAKDOWN
    • 9.4.4 PRODUCT BENCHMARKING
    • 9.4.5 KEY DEVELOPMENT
    • 9.4.6 SWOT ANALYSIS
  • 9.5 ASTELLAS PHARMA
    • 9.5.1 COMPANY OVERVIEW
    • 9.5.2 COMPANY INSIGHTS
    • 9.5.3 SEGMENT BREAKDOWN
    • 9.5.4 PRODUCT BENCHMARKING
    • 9.5.5 SWOT ANALYSIS
  • 9.6 ELI LILLY AND COMPANY
    • 9.6.1 COMPANY OVERVIEW
    • 9.6.2 COMPANY INSIGHTS
    • 9.6.3 SEGMENT BREAKDOWN
    • 9.6.4 PRODUCT BENCHMARKING
    • 9.6.5 KEY DEVELOPMENT
  • 9.7 BAYER AG
    • 9.7.1 COMPANY OVERVIEW
    • 9.7.2 COMPANY INSIGHTS
    • 9.7.3 SEGMENT BREAKDOWN
    • 9.7.4 PRODUCT BENCHMARKING
    • 9.7.5 KEY DEVELOPMENT
  • 9.8 LIPELLA PHARMACEUTICALS
    • 9.8.1 COMPANY OVERVIEW
    • 9.8.2 COMPANY INSIGHTS
    • 9.8.3 PRODUCT BENCHMARKING
  • 9.9 SEIKAGAKU CORPORATION
    • 9.9.1 COMPANY OVERVIEW
    • 9.9.2 COMPANY INSIGHTS
    • 9.9.3 SEGMENT BREAKDOWN
    • 9.9.4 PRODUCT BENCHMARKING
    • 9.9.5 KEY DEVELOPMENT
  • 9.10 GRUNENTHAL
    • 9.10.1 COMPANY OVERVIEW
    • 9.10.2 COMPANY INSIGHTS
    • 9.10.3 PRODUCT BENCHMARKING

LIST OF TABLES

  • TABLE1 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 2 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 3 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY GEOGRAPHY, 2021 - 2028 (USD MILLION)
  • TABLE 4 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE 5 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 6 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 7 U.S. INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 8 U.S. INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 9 CANADA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE10 CANADA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE11 MEXICO INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE12 MEXICO INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE13 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE14 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE15 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE16 GERMANY INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE17 GERMANY INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE18 FRANCE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE19 FRANCE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 20 U.K. INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 21 U.K. INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 22 REST OF EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 23 REST OF EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 24 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE 25 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 26 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 27 JAPAN INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 28 JAPAN INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 29 CHINA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 30 CHINA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 31 INDIA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 32 INDIA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 33 REST OF ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 34 REST OF ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 35 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE 36 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 37 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 38 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 39 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 40 LATIN AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 41 LATIN AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 42 COMPANY MARKET RANKING ANALYSIS
  • TABLE 43 PFIZER INC.: PRODUCT BENCHMARKING
  • TABLE 44 PFIZER INC.: KEY DEVELOPMENT
  • TABLE 45 JOHNSON & JOHNSON: PRODUCT BENCHMARKING
  • TABLE 46 KYORIN PHARMACEUTICAL: PRODUCT BENCHMARKING
  • TABLE 47 KYORIN PHARMACEUTICAL: KEY DEVELOPMENT
  • TABLE 48 UCB PHARMA: PRODUCT BENCHMARKING
  • TABLE 49 UCB PHARMA: KEY DEVELOPMENT
  • TABLE 50 ASTELLAS PHARMA: PRODUCT BENCHMARKING
  • TABLE 51 ELI LILLY AND COMPANY: PRODUCT BENCHMARKING
  • TABLE 52 ELI LILLY AND COMPANY: KEY DEVELOPMENT
  • TABLE 53 BAYER AG: PRODUCT BENCHMARKING
  • TABLE 54 BAYER AG: KEY DEVELOPMENT
  • TABLE 55 LIPELLA PHARMACEUTICALS: PRODUCT BENCHMARKING
  • TABLE 56 SEIKAGAKU CORPORATION: PRODUCT BENCHMARKING
  • TABLE 57 SEIKAGAKU CORPORATION: KEY DEVELOPMENT
  • TABLE 58 GRUNENTHAL: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE1 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET OVERVIEW
  • FIGURE 6 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET GEOGRAPHICAL ANALYSIS, 2021-2028
  • FIGURE 7 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE USD MILLION)
  • FIGURE 8 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL (USD MILLION)
  • FIGURE 9 FUTURE MARKET OPPORTUNITIES
  • FIGURE10 NORTH AMERICA DOMINATED THE MARKET IN 2020
  • FIGURE11 MARKET OVERVIEW
  • FIGURE12 PORTER'S FIVE FORCES ANALYSIS: GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
  • FIGURE13 PRODUCT LIFELINE: GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
  • FIGURE14 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE
  • FIGURE15 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL
  • FIGURE16 COMPOUND ANNUAL GROWTH RATE OF MARKET IN PROMINENT COUNTRIES ACROSS THE GLOBE
  • FIGURE17 NORTH AMERICA MARKET SNAPSHOT
  • FIGURE18 THE U.S. MARKET SNAPSHOT
  • FIGURE19 CANADA MARKET SNAPSHOT
  • FIGURE 20 MEXICO MARKET SNAPSHOT
  • FIGURE 21 EUROPE MARKET SNAPSHOT
  • FIGURE 22 GERMANY MARKET SNAPSHOT
  • FIGURE 23 FRANCE MARKET SNAPSHOT
  • FIGURE 24 U.K. MARKET SNAPSHOT
  • FIGURE 25 ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 26 JAPAN MARKET SNAPSHOT
  • FIGURE 27 CHINA MARKET SNAPSHOT
  • FIGURE 28 INDIA MARKET SNAPSHOT
  • FIGURE 29 ROW SNAPSHOT
  • FIGURE 30 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • FIGURE 31 LATIN AMERICA MARKET SNAPSHOT
  • FIGURE 32 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 33 PFIZER INC.: COMPANY INSIGHT
  • FIGURE 34 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 35 JOHNSON & JOHNSON: COMPANY INSIGHT
  • FIGURE 36 JOHNSON & JOHNSON: BREAKDOWN
  • FIGURE 37 JOHNSON & JOHNSON: SWOT ANALYSIS
  • FIGURE 38 KYORIN PHARMACEUTICAL: COMPANY INSIGHT
  • FIGURE 39 KYORIN PHARMACEUTICAL: BREAKDOWN
  • FIGURE 40 KYORIN PHARMACEUTICAL: SWOT ANALYSIS
  • FIGURE 41 UCB PHARMA: COMPANY INSIGHT
  • FIGURE 42 UCB PHARMA: BREAKDOWN
  • FIGURE 43 UCB PHARMA: SWOT ANALYSIS
  • FIGURE 44 ASTELLAS PHARMA: COMPANY INSIGHT
  • FIGURE 45 ASTELLAS PHARMA: BREAKDOWN
  • FIGURE 46 ASTELLAS PHARMA: SWOT ANALYSIS
  • FIGURE 47 ELI LILLY AND COMPANY: COMPANY INSIGHT
  • FIGURE 48 ELI LILLY AND COMPANY: BREAKDOWN
  • FIGURE 49 BAYER AG: COMPANY INSIGHT
  • FIGURE 50 BAYER AG: BREAKDOWN
  • FIGURE 51 LIPELLA PHARMACEUTICALS: COMPANY INSIGHT
  • FIGURE 52 SEIKAGAKU CORPORATION: COMPANY INSIGHT
  • FIGURE 53 SEIKAGAKU CORPORATION: BREAKDOWN
  • FIGURE 54 GRUNENTHAL: COMPANY INSIGHT